From Intermediate AMD to Geographic Atrophy: Biomarkers, Endpoints, and a Roadmap for Next-Generation Clinical Trials.
Age-related macular degeneration (AMD) is a leading cause of irreversible legal blindness worldwide. Treatments exist for late-stage AMD, but none exists for the intermediate stage (iAMD), which precedes significant vision loss. A therapy tested in iAMD would aim to prevent or slow progression to late-stage disease, me...